跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ALZERTA 13,3 MG/24 H PARCHES TRANSDERMICOS EFG - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
ALZERTA 13,3 MG/24 H PARCHES TRANSDERMICOS EFG
Approved
STANDARD
ALZERTA 13,3 MG/24 H PARCHES TRANSDERMICOS EFG
Esteve Pharmaceuticals S.A.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Dec 14, 2020
Approval ID
f43cbb75334e221a
Company
Esteve Pharmaceuticals S.A.
Type
Standard
Approval Details
Approval Id
f43cbb75334e221a
Drug Cima Aemps Name
ALZERTA 13,3 MG/24 H PARCHES TRANSDERMICOS EFG
Register Number
85558
Holder Company Name
Esteve Pharmaceuticals S.A.
Marketing Company Name
Esteve Pharmaceuticals S.A.
Holder Company Detail Path
/organization/esteve-pharmaceuticals-s-a
Marketing Company Detail Path
/organization/esteve-pharmaceuticals-s-a
Authorization Date
2020-12-14
Dosage Form
PARCHE TRANSDÉRMICO
Dose
13,3 mg/24 h
Route Of Administration
VÍA TRANSDÉRMICA
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Esteve Pharmaceuticals S.A.
Company Detail Path
/organization/esteve-pharmaceuticals-s-a
Company Information
Pharmaceutical Company Name
Esteve Pharmaceuticals S.A.
Country Name
Spain
Website
http://www.esteve.com
Active Ingredients
RIVASTIGMINA
19,2 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Dec 14, 2020
Approval ID
f43cbb75334e221a
Type
Standard
Back to CIMA-AEMPS Approvals
